← Browse by Condition
Medical Condition

carcinoma renal cell

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for carcinoma renal cell sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — carcinoma renal cell Clinical Trials

How many clinical trials are currently recruiting for carcinoma renal cell?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for carcinoma renal cell, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for carcinoma renal cell?
carcinoma renal cell research spans Phase 1 (1 trial), Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a carcinoma renal cell clinical trial?
Eligibility criteria for carcinoma renal cell trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
1
Phase 3
1
Top Sponsors
State University of New York at Buffalo 1 trial
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 1 trial
Merck Sharp & Dohme LLC 1 trial

Recruiting Clinical Trials

NCT06222593 Phase 1, Phase 2
Recruiting
Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC
Enrollment
28 pts
Location
United States
Sponsor
State University of New York a...
View Trial →
NCT04113486
Recruiting
Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations
Enrollment
400 pts
Location
China
Sponsor
Xinhua Hospital, Shanghai Jiao...
View Trial →
NCT07489495 Phase 3
Recruiting
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Enrollment
758 pts
Location
United States, Argen...
Sponsor
Merck Sharp & Dohme LLC
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology